AKBA · Akebia Therapeutics, Inc.

The thesis

Akebia Therapeutics has a growing kidney drug in Vafseo, but the shares keep falling because its older drug Auryxia is eroding faster and Vafseo's price resets in 2027. The adjusted close on 27 October 2026 was $0.66, 79.2% below the 52-week high of $3.17 and 51.1% lower over three months. The Q3 report, estimated for about 9 November 2026, settles whether Vafseo revenue above the $21.3 million of Q2 2026 can offset Auryxia.

The narrative is dead as a trading story: Akebia issued releases on 26 October 2026 and 27 October 2026 on positive VOICE trial data from American Society of Nephrology (ASN) Kidney Week, and the close of $0.66 on 27 October 2026 sits below the $0.70 close of 14 October 2026. The 14-day relative strength index (a momentum gauge where readings under 30 mark heavy selling) was 25.2 on 27 October 2026.

The clinical news confirmed what the 30 June 2026 interim filing had already shown. The price did not respond, which places the focus on revenue and on the 2027 price cut. Management said on 5 August 2026 that it expects lower 2027 revenue as Vafseo's add-on payment ends.

Bullish and bearish views on Akebia Therapeutics, Inc.

The bull case on Akebia Therapeutics, Inc. (AKBA), in brief: Vafseo uptake is measurable. The bear case: Auryxia erosion outweighs Vafseo growth.

Bull case

• Vafseo uptake is measurable. Akebia reported Q2 2026 Vafseo revenue of $21.3 million against $13.3 million a year earlier, with more than 10,500 active patients and about 1,200 prescribers (Q2 release, 5 August 2026).
• The full VOICE data are public. Akebia and U.S. Renal Care presented the trial at ASN Kidney Week 2026 (company releases, 26 October 2026 and 27 October 2026). The 30 June 2026 interim analysis of 2,116 dialysis patients met its stopping criteria on the mortality-and-hospitalization composite, with a hospitalization incidence rate ratio of 0.90, per the company's release and Form 8-K.
• Pipeline work continues. Akebia announced first-patient dosing in its Phase 2 ebribafusp basket trial in rare complement-mediated kidney diseases on 14 September 2026, with initial data expected in 2027.
• Analyst targets sit far above the price. WestPark Capital's target is $4.50 (8 September 2026) and HC Wainwright's is $6 (reiterated 1 July 2026), against a $0.66 close on 27 October 2026.

Bear case

• Auryxia erosion outweighs Vafseo growth. Q2 2026 Auryxia revenue was $25.5 million against $47.2 million a year earlier, and total revenue was $49.1 million against $62.5 million (Q2 release, 5 August 2026).
• A price reset arrives in 2027. Management said on the 5 August 2026 call that Vafseo pricing moves toward erythropoiesis-stimulating agent (ESA) prices after the transitional add-on payment ends on 31 December 2026.
• VOICE did not separate mortality. The 30 June 2026 Form 8-K reported no statistically significant difference in mortality rates, so the benefit rests on fewer hospitalizations. The Vafseo label carries a thrombotic-event warning.
• The shares trade well under $1.00. The $0.66 close on 27 October 2026 follows closes of $0.92 on 30 September 2026 and $0.70 on 14 October 2026. Nasdaq issues a deficiency notice after 30 consecutive business days of closes below $1.00, and Akebia went through the same process in 2023.
• Financing depends on a refinancing. The Q2 2026 release conditions the two-year cash runway statement on refinancing the senior secured term loan. A share price this low raises the cost of any equity raise.

Price setup

The shares closed at $0.66 on 27 October 2026, down from $0.70 on 14 October 2026 and $0.92 on 30 September 2026, according to adjusted daily closes. The 52-week high is $3.17. The three-month decline is 51.1%.

The 14-day relative strength index of 25.2 shows persistent selling. The $0.60 close named as the invalidation level sits 9.1% below the 27 October 2026 close.

Crowding evidence points the other way from a squeeze: no insider purchases or large new filings are reported, and the shares fell after positive trial news. Routine new-hire inducement grants add shares at the margin; the latest was announced 1 October 2026. The Q3 report is the next dated event.

Catalysts, next 30 days

• ~9 November 2026, est.: Q3 2026 results. Earnings Whispers, a third-party calendar, lists 9 November 2026 after the close; the company has not confirmed. Last year Akebia reported on 10 November 2025. The report shows whether Vafseo revenue exceeds $21.3 million, total revenue exceeds $49.1 million, and whether management changes its lower-2027-revenue expectation.
• 31 December 2026: Vafseo add-on payment period ends. Outside the 30-day window, but the 2027 revenue case turns on it.

Elapsed catalysts

• ~30 October 2026 to ~5 November 2026, est.: Q3 results date announcement. Akebia announced the Q2 date on 29 July 2026, seven days before reporting. A date announcement would confirm the timing. (passed 1d ago)

What would change the view

The case breaks if Q3 2026 total revenue prints under $49.1 million with Auryxia falling faster than Vafseo grows, or if management frames 2027 Vafseo revenue below the Q2 2026 level of $21.3 million. A Form 8-K disclosing an equity offering, a convertible issuance or an amended credit agreement on weak terms would also break it. On price, a daily close below $0.60 would extend the decline from the $0.66 close of 27 October 2026.

The case improves if Q3 shows Vafseo revenue clearly above $21.3 million, if the term loan is refinanced without dilution, or if a named large dialysis operator commits to a protocol with a start date. Any of these would be new evidence against the current LOW rating.

What it trades with

Akebia is a single-franchise micro-cap that reacts to its own financing, earnings and payment-policy news. Its moves track small-cap biotech and Medicare dialysis reimbursement news more than the broad market. Reimbursement changes affecting dialysis providers and ESA pricing are the external inputs that matter most to Vafseo's 2027 revenue.